--- title: "Pre-market hot trades in US stocks: Callan Jmb up 3.53% in pre-market; Marvell Tech up 3.26% in pre-market" type: "News" locale: "en" url: "https://longbridge.com/en/news/293929920.md" description: "Callan Jmb pre-market up 3.53%; Marvell Tech pre-market up 3.26%; Lion Group Holding pre-market up 127.18%; T3 Defense pre-market up 60.46%; Matinas BioPharma pre-market up 59.65%" datetime: "2026-07-27T12:08:12.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/293929920.md) - [en](https://longbridge.com/en/news/293929920.md) - [zh-HK](https://longbridge.com/zh-HK/news/293929920.md) --- # Pre-market hot trades in US stocks: Callan Jmb up 3.53% in pre-market; Marvell Tech up 3.26% in pre-market **Popular Pre-Market Trades in US Stocks** Callan Jmb, up 3.53% in pre-market, with no significant news recently. Trading is active, and capital flows are evident. Considering sector and industry trends, the stock shows notable volatility, with specific reasons needing further observation. Marvell Tech is up 3.26% in pre-market. Based on recent key news: 1. On July 26, Guangxun Technology released a 6.4T silicon photonic NPO, with the core DSP chip supplied by Marvell. This move demonstrates Marvell's continued influence in the silicon photonic technology field, potentially driving its stock price up. Source: Zhitong Finance 2. On July 25, MarketBeat reported that although Marvell Technology was rated as "Moderate Buy," top analysts are more optimistic about five other stocks. This may have some impact on investor confidence. Source: MarketBeat 3. On July 24, Nvidia was confirmed as a significant investor in Marvell, which may enhance market confidence in Marvell and drive its stock price up. Source: Zhitong Finance. AI stocks are rising, while oil prices are falling, affecting energy stocks. **Top Gainers in Pre-Market US Stocks** Lion Group Holding is up 127.18% in pre-market. Based on recent key news: 1. On July 23, HRT Financial sold 34,989 shares of Lion Group Holding, reducing its holdings to 63,695 shares. This move may raise market attention on changes in the company's shareholder structure, subsequently affecting stock price volatility. Source: EDGAR 2. On July 24, Spark analysts rated Lion Group Holding as neutral, noting the company's weak financial performance and bearish technical outlook, despite the stock being oversold, it remains below major moving averages. This analysis may impact investor confidence. Source: TipRanks 3. No other significant news recently. Market attention on AI technology is increasing. T3 Defense is up 60.46% in pre-market. Based on recent key news: 1. On July 24, T3 Defense submitted a SCHEDULE 13D filing, indicating its strategic acquisition plans. The company focuses on acquiring and improving operational businesses, planning to expand its strategic holdings through follow-up transactions and close collaboration with management. This news has sparked optimistic expectations in the market regarding the company's future growth potential, significantly driving up its stock price. The market is optimistic about the acquisition strategy. Matinas BioPharma is up 59.65% in pre-market. Based on recent key news: 1. On July 24, Matinas BioPharma announced the termination of its sales agreement with BTIG, effective immediately. The agreement allowed the company to sell up to $50 million of common stock through the market. BTIG terminated the agreement under contractual rights without any termination fees or expenses. This change removes that market financing option unless Matinas establishes a new plan After this news was released, the stock price surged significantly. Source: Reuters 2. On July 24, Spark's AI analyst held a neutral stance on MTNB stock, mainly due to very weak financial performance (no revenue, ongoing losses, and cash burn), with technical indicators also remaining negative, as the stock traded well below key moving averages and MACD was bearish. Nevertheless, strategic changes and asset sales had a positive impact on the stock price. Source: TipRanks 3. On July 24, Matinas BioPharma terminated its market sales agreement with BTIG, effective immediately. This agreement allowed the company to sell up to $50 million of common stock through the market. BTIG terminated the agreement under contractual rights without any termination fees or expenses. This change removed that market financing option unless Matinas establishes a new plan. After this news was released, the stock price surged significantly. Source: SEC Industry Trends: The biopharmaceutical industry has recently performed strongly, with significant capital inflows ### Related Stocks - [CJMB.US](https://longbridge.com/en/quote/CJMB.US.md) - [MRVL.US](https://longbridge.com/en/quote/MRVL.US.md) - [LGHL.US](https://longbridge.com/en/quote/LGHL.US.md) - [DFNS.US](https://longbridge.com/en/quote/DFNS.US.md) - [MTNB.US](https://longbridge.com/en/quote/MTNB.US.md) ## Related News & Research - [Callan JMB partners with Alabama State University on Atlas Complex biomanufacturing venture](https://longbridge.com/en/news/294212208.md) - [Is Marvell Technology (MRVL) Overvalued Following Its $250 Million India Investment?](https://longbridge.com/en/news/294405968.md) - [Arkadios Wealth Advisors Has $4.73 Million Stock Holdings in Marvell Technology, Inc. $MRVL](https://longbridge.com/en/news/294574948.md) - [Marvell Technology, Inc. $MRVL Shares Sold by Janus Henderson Group PLC](https://longbridge.com/en/news/294492176.md) - [Principal Financial Group Inc. Sells 6,022 Shares of Madrigal Pharmaceuticals, Inc. $MDGL](https://longbridge.com/en/news/294578126.md)